General Motors (GM), Abbott Laboratories (ABT), and Johnson & Johnson (JNJ) reported strong earnings in the ongoing Q2 2026 earnings season, raising their fiscal guidance amid positive performance. GM reported a 14% positive surprise in earnings per share (EPS) with sales of $48.0 billion, surpassing estimates by 3%. Abbott’s adjusted EPS reached $1.31, outperforming expectations by 2.3%, while sales hit $12.6 billion, closely matching forecasts.
GM raised its full-year EBIT adjusted guidance for the second time this year, while Abbott increased its adjusted EPS guidance to $5.45-$5.60. Johnson & Johnson continued its streak with nine consecutive quarters of earnings beats, increasing its sales and EPS guidance, positioning it to surpass $100 billion in annual revenue for the first time. These guidance upgrades typically lead to favorable stock reactions, underlining the companies’ strong fundamentals.
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.
